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SCIENTIFIC EDITORIAL
Digoxin therapy: A persisting interest despite
contrary winds
Traitement par digoxine : un intérêt persistant malgré des vents contraires !
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Abstract Digoxin therapy is used to treat heart failure patients for more than 200 years. How-
ever, absence of effect on overall mortality found in the DIG study associated with frequent
adverse effects due to overdosing in elderly patients with impaired renal function ﬁnally per-
suaded medical opinion to the weak interest of digoxin in chronic heart failure. Its image of old-
fashioned drug in the mind of young cardiology generations appears widely distorted, and suffers
from the absence of promotion by pharmaceutical industry, given a very low cost and a rapid
arrival onto the generic market. Yet, regarding strict data from the literature, it remains a lot
of positive factors in favor of the interest for digoxin: reduction of morbidity, reduction of mor-
tality at low serum concentration < 1.0 ng/ml, very low cost with favorable cost-effectiveness
ratio. This article challenges some arguments for defending digoxin as another ﬁrst-line therapy
as well as ACE inhibitors and beta-blockers in the treatment of chronic heart failure.
© 2010 Elsevier Masson SAS. All rights reserved.
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hat is the question?
igitalis glycosides were among the ﬁrst cardiovascular ther-
peutic agents to be used in medicine. Digoxin, obtained
rom the leaves of Digitalis lanata, is the most common
reparation of digitalis, and has been used to treat heart
ailure patients for more than 200 years. However, digoxin
cquired a negative image at the end of the 1980s, as a result
f clinical trials testing new oral inotropic agents, in which
igh mortality rates were linked to this class of cardiovas-
ular agent. Consecutively, the pathophysiological concept
f heart failure was changed from a haemodynamic model
o a neurohormonal model with the advent of the era of
ngiotensin-converting enzyme (ACE) inhibitors [1], which
esulted in digoxin being positioned in a secondary role in
he therapeutic management of heart failure. Absence of
ffect on overall mortality in the DIG study [2], associated
ith frequent adverse effects due to overdosing in elderly
atients with impaired renal function, ﬁnally diminished
edical interest in the use of digoxin in chronic heart fail-
re. Data from heart failure registries and clinical trials show
considerable fall in digoxin use from approximately 80% to
ess than 30% in the past 10 years [3]. Yet, if the actual data
rom the literature are considered, there are many positive
actors to support digoxin use. The opinion held by younger
ardiologists of digoxin as an old-fashioned drug appears to
e widely misplaced, and the drug suffers from the absence
f promotion by the pharmaceutical industry, given its very
ow cost and rapid arrival onto the generic market. What we
ow need to know is whether the effectiveness of digoxin
s underestimated, and whether it could represent an
nteresting therapeutic alternative that is worthy of recon-
ideration in the treatment of patients with chronic heart
ailure.
hat can we expect from digoxin?
igoxin has shown numerous favourable effects over many
ears [4,5]. It improves clinical symptoms, exercise capac-
ty, and cardiac haemodynamics at rest and at exercise by
ecreasing left ventricular ﬁlling pressures and pulmonary
apillary wedge pressure, increasing cardiac output and
lowing heart rate. It also exerts favourable neurohormonal
ffects by enhancing parasympathetic tone and reducing
ncreased plasma levels of norepinephrine, aldosterone and
enin activity, each of which is stimulated in heart fail-
re. All these effects enable digoxin to improve renal
unction.
Previous digoxin discontinuation trials, PROVED [6] and
ADIANCE [7], showed an indirect favourable effect of
igoxin, in that withdrawal in patients with heart fail-
re receiving the drug chronically in association with ACE
nhibitors led to an increase in worsening heart failure
nd mortality. The DIG study [2], published in 1997 and
erformed in more than 6700 patients with systolic heart
ailure, did not show any effect on overall mortality; how-
ver, there was a highly signiﬁcant, positive effect on the
ombined endpoint of heart failure mortality and hospital-
zation for heart failure (25% reduction), mainly due to a
ubstantial 28% reduction in hospitalization for heart fail-
re. Nevertheless, complementary analyses highlighted an
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ncrease in presumed arrhythmic deaths [2] and an excess
n overall mortality in women, without any convincing expla-
ation [8].
In order to better understand why these contradictory
egative effects of digoxin on mortality and major pos-
tive effects on morbidity exist, post-hoc analyses were
erformed using digoxin serum concentrations from patients
ncluded in the DIG trial. It appeared that digoxin improved
eft ventricular ejection fraction (LVEF) below serum con-
entrations of 1.2 ng/mL, but that the effect disappeared
bove this threshold [9]. Again, digoxin withdrawal caused
decrease in LVEF, associated with an increase in cardiovas-
ular events. All-cause mortality was reduced signiﬁcantly
by 23%) when serum digoxin concentrations in 30-day sur-
ivors were between 0.5 and 0.9 ng/mL, and this was always
ccompanied by a very clear reduction in morbidity (38%
elative reduction in the need for heart failure hospitaliza-
ion), which was also seen at serum concentrations between
.0 and 1.5 ng/mL [10,11]. No interaction between digoxin
nd gender was noticed [12], thereby suggesting that ear-
ier results showing increased mortality in women [8] was
erhaps a spurious result due to residual confounding from
erum concentrations.
Recently, some studies were published concerning the
ffects of digoxin in heart failure [13,14], which did not
how any improvement in mortality-morbidity criteria after
rescription of digoxin. However, these studies were sin-
le centre and retrospective, without prespeciﬁed and
andomized groups. When serum concentrations were mea-
ured [14], the median serum digoxin concentration was
.75 ng/mL, ranging from a ﬁrst quartile of 0.50 ng/mL to a
ourth quartile of 1.40 ng/mL for a median daily drug dosage
f 0.130mg/day. As established by DIG post-hoc analyses,
hese values appeared to be too high —at least for 25—33%
f the study patients. Some criticisms of these studies were
ade in a recent editorial [15]: for instance, the inclusion
f younger patients with more severe heart failure (in terms
f New York Heart Association [NYHA] class) than would usu-
lly be included in large randomized trials, such as the DIG
rial.
he case for prescribing digoxin
uropean guidelines for the treatment of heart failure,
evised in 2008 [16], recommend prescription of digoxin
n patients with symptomatic heart failure and atrial ﬁb-
illation (Class IC), and in patients in sinus rhythm with
ymptomatic heart failure and LVEF≤ 40% (Class IIa, level of
vidence B). When looking at the evolution of digoxin rec-
mmendations over time, we see that the guidelines were
nconsistent from 2001 (no recommendation for patients in
inus rhythm) to 2005 (recommendation for patients in sinus
hythm, Class IIa, level of evidence A), and ﬁnally to 2008
same recommendation but Class IIa, level of evidence B),
espite no new data having published; this illustrates the
arge variability in opinion and interpretation of the litera-
ure by the experts. The recommended treatment algorithm
roposed for patients with symptomatic heart failure and
educed LVEF ranks digoxin among treatments of third
ntention after angiotensin receptor blockers (ARBs) and
ldosterone antagonists if the QRS width is less than or equal
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to 120ms; if the QRS width is greater than 120ms, resyn-
chronization therapy is preferred [16]. Yet, the arguments
for prescribing digoxin or any blockers of the renin-
angiotensin system other than ACE inhibitors are not very
different.
Digoxin has a neutral effect on mortality but improves the
combined endpoint of morbimortality in patients in NYHA
class II—IV heart failure with LVEF less than or equal to 45%.
The efﬁcacy of digoxin was established in a unique, large,
randomized, controlled trial that included more than 6700
patients [2]. The proof of efﬁcacy for ARBs and aldosterone
blockers in heart failure is not really superior to that for
digoxin.
A role for aldosterone antagonists was identiﬁed as a
result of the RALES study [17], which showed a reduction
in overall mortality in patients in severe NYHA class III—IV
heart failure with LVEF less than or equal to 35%. It is well
known that drug efﬁcacy is often easier to demonstrate
in patients with severe disease than in those with mild to
moderate disease. Moreover, patients in the RALES study
received a rather low dose of ACE inhibitors (63mg/day for
captopril, 15mg/day for enalapril or 14mg/day for lisino-
pril). In addition, in a subgroup analysis of the RALES trial
involving patients who were in the spironolactone group,
the beneﬁt was not statistically signiﬁcant in those who
did not receive digoxin or ACE inhibitors. Nevertheless,
the efﬁcacy of aldosterone antagonists was conﬁrmed by
the results of a second study (the EPHESUS trial), which
tested eplerenone [18]. However, the patient proﬁle was
totally different (patients with left ventricular systolic dys-
function in the acute phase of myocardial infarction), and
a post-hoc analysis showed clearly that the favourable
effect on morbimortality attributed to eplerenone was only
present when the drug was initiated between the third
and seventh days after acute myocardial infarction; a later
prescription had no signiﬁcant effect at all on outcomes
[19].
Proof of efﬁcacy of ARBs in association with ACE inhibitors
also came from a unique study — the CHARM-Added trial
[20]. The efﬁcacy of candesartan was expressed in terms
of morbimortality criteria. As with digoxin in the DIG trial,
no positive effect was found on overall mortality. More-
over, the efﬁcacy of other ARBs (losartan, valsartan) in
association with ACE inhibitors is questionable, and the
triple association of an ACE inhibitor, ARB and beta-blocker
was shown to have a deleterious effect in the Val-HeFT
trial [21]. Digoxin thus stands comparison with these other
competitors.
Digoxin therapy has another major argument in its favour:
a low price with an extremely positive cost-effectiveness
ratio. According to the DIG trial, the treatment of only
11 patients for 3 years should be sufﬁcient to avoid one
costly hospitalization for heart failure (total cost: around
D 1000). By comparison, it is necessary to treat 70 patients
for 4 years with an ACE inhibitor to avoid one non-
fatal myocardial infarction (total cost: D 60,000—90,000
depending on the ACE inhibitor used) [22]. Previous anal-
yses from the PROVED and RADIANCE trials showed that
the use of digoxin in patients with stable heart fail-
ure would result in net annual savings of $ 406 million,
with a 90% range of probability of $ 106—822 million
[23].283
onclusions
igoxin is an effective drug for patients with heart failure,
nd should be used as a ﬁrst-line therapy in association with
CE inhibitors and beta-blockers for patients with clinical
eart failure and left ventricular dysfunction, with LVEF less
han or equal to 45%. The drug has a large morbidity bene-
t, certainly at least as large as that seen for ACE inhibitors
n heart failure, and should not be ignored by prescribers.
oreover, the large randomized heart failure trials that
howed the beneﬁts of ACE inhibitors, beta-blockers, ARBs
nd resynchronization therapy were generally performed
ith background digoxin therapy (up to 75% of the patients
n the RALES trial!). Other trials would be useful to conﬁrm
he post-hoc analyses of the DIG trial. However, it proba-
ly is a vain wish, unless institutional funding can be found,
iven how neglected the marketing of the drug is. Digoxin’s
ank on the scale of chronic heart failure therapy appears to
e underestimated and it deserves to be reconsidered at a
uggested dosage of less than or equal to 0.125mg/day given
mmediately to attain a serum digoxin concentration of less
han 1.0 ng/mL. The risk of adverse effects would thus be
educed dramatically, while a major gain would be achieved
n terms of public health. Digoxin might also be reconsidered
n the therapeutic management of acute decompensated
eart failure [24]. Let us hope that in the near future, gov-
rnment agencies do not decide to sideline digoxin in the
ardiovascular pharmacopoeia on the pretext of its age and
o-called weak efﬁcacy!
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